[Early antibiotic treatment for eradication of initial infection by Pseudomonas aeruginosa in patients with cystic fibrosis].
BACKGROUND
Cystic fibrosis is a genetic autosomal recessive disease that affects approximately 1:6000 live births in our country. Chronic infection with Pseudomonas aeruginosa (PA) is associated with higher morbidity and-mortality, and deterioration of lung function. Treatment of initial infection is important to prevent or delay chronic infection. The primary aim was to determine the effectiveness and freetime of PA in bronchial secretions after eradication treatment. The secondary objective was to determine changes in the weight and lung function.


METHODS
Prospective, observational study, of patients with cystic fibrosis (CF) and recent PA infection. After initial infection by PA patients received oral ciprofoxacin and nebulized colistin. We studied effectiveness of treatment to eradicate PA, and changes in the weight measured in Z score and in the respiratory functional tests, pre-infection, during, and after the eradication of PA.


RESULTS
We included 24 patients (11 male) with confirmed CF. Seven of them had two PA infections, and received 2 treatment courses. PA was eradicated in 24 (80.5%) out of 31 infections. The value of weight measured in Z score, and functional tests measures through the FVC and FEV1 decreased during the infection by PA, returning to the baseline after eradication. The free-time of PA during the follow-up to these patients was 23.75 (95% CI 14.38-32.86) months.


CONCLUSIONS
Treatment of initial infection by PA has a high degree of response. Weight and functional values improved after treatment.
Giugno
Hilda
H
Servicio de Neumonología, Hospital Nacional de Pediatría Prof. Dr. Juan P. Garrahan, Buenos Aires. hildagiugno@yahoo.com
Castaños
Claudio
C
Lubatti
Alberto
A
Pinheiro
José Luis
JL
Hernández
Claudia
C
González Pena
Hebe
H
D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D002675:Child, Preschool; D003550:Cystic Fibrosis / Q000150:complications*; D005260:Female; D006801:Humans; D008297:Male; D011446:Prospective Studies; D011552:Pseudomonas Infections / Q000188:drug therapy* / Q000209:etiology*; D011550:Pseudomonas aeruginosa; D013997:Time Factors
D000900:Anti-Bacterial Agents